Table 1.
Population characteristics.
| Patients Clinical Features | HD | PD | TX | |
|---|---|---|---|---|
| Age (years) | 69 ± 12 | 63 ± 11 | 60 ± 11 | |
| Male% (n) | 66% (98) | 60% (12) | 69% (29) | |
| Treatment vintage (months) | 59.3 ± 55.3 | 37 ± 17 | 12.6 ± 7.9 | |
| ESRD etiology % (n) | Not Known | 26.4% (39) | 15% (3) | 23.8% (10) |
| Diabetes | 25.7% (38) | 15% (3) | 2.4% (1) | |
| Hypertensive | 17.6% (26) | 20% (4) | 14.3% (6) | |
| Urologic disease | 6.8% (10) | - | 9.5% (4) | |
| ADPKD | 5.4% (8) | 20% (4) | 2.4% (1) | |
| IgA N | 3.4% (5) | 15% (3) | 16.7% (7) | |
| Membranous N. | 2.7% (4) | - | - | |
| MPGN | 2% (3) | - | 7.1% (3) | |
| FSGS | - | - | 11.9% (5) | |
| Myeloma | 2% (3) | - | - | |
| Amyloidosis | 1.4% (2) | - | - | |
| Vasculitis | 1.4% (2) | - | - | |
| Other genetic diseases | - | - | 7.1% (3) | |
| Others | 5.4% (8) | 15% (3) | 4.8% (2) | |
| Comorbidities % (n) | Hypertension | 86.5% (128) | 95% (19) | 97.6% (41) |
| Diabetes | 33.1% (49) | 20% (4) | 19% (8) | |
| Heart disease | 31.8% (47) | 30% (6) | 7.1% (3) | |
| COPD | 20.9% (31) | - | - | |
| Neoplasia | 11.5% (17) | - | - | |
| Immunosuppressive therapy % (n) | Steroids | 80.9% (34) | ||
| Cyclosporine | 71.4% (10) | |||
| Tacrolimus | 23.8% (10) | |||
| Mycophenolate | 71.4% (30) | |||
| Azathioprine | 11.9% (5) | |||
| Everolimus | 11.9% (5) | |||
| Unspecified | 6.1% (9) | 5% (1) | - | |
ADPKD: Autosomal Dominant Polycystic Kidney Disease; MPGN: Membranoproliferative Glomerulonephritis; FSGS: Focal segmental glomerulosclerosis; COPD: Chronic obstructive pulmonary disease.